Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. Panbela’s lead assets are Ivospemin (SBP-101) and Flynpovi. Further information can be found at www.panbela.com . Panbela’s common stock is listed on The Nasdaq Stock Market LLC under the symbol “PBLA”.
Company profile
Ticker
PBLA
Exchange
Website
CEO
Michael Cullen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cimarron Medical, Inc., CIMARRON SOFTWARE INC, Sun BioPharma, Inc.
SEC CIK
Corporate docs
Subsidiaries
Cancer Prevention Pharmaceuticals, Inc. • Cancer Prevention Pharmaceuticals, LLC • Cancer Prevention Pharma (Ireland) Limited • Cancer Prevention Pharma Limited • Panbela Research, Inc. • Victoria, Australia ...
PBLA stock data
Latest filings (excl ownership)
S-1
IPO registration
18 Apr 24
8-K
Panbela Announces Transfer to OTCQB Market
17 Apr 24
EFFECT
Notice of effectiveness
17 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
EFFECT
Notice of effectiveness
3 Apr 24
S-1
IPO registration
29 Mar 24
POS AM
Prospectus update (post-effective amendment)
29 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
26 Mar 24
PRE 14A
Preliminary proxy
25 Mar 24
Transcripts
PBLA
Earnings call transcript
2023 Q4
26 Mar 24
PBLA
Earnings call transcript
2023 Q3
9 Nov 23
PBLA
Earnings call transcript
2023 Q2
10 Aug 23
PBLA
Earnings call transcript
2023 Q1
4 May 23
PBLA
Earnings call transcript
2022 Q4
16 Mar 23
PBLA
Earnings call transcript
2022 Q3
10 Nov 22
PBLA
Earnings call transcript
2022 Q2
15 Aug 22
PBLA
Earnings call transcript
2022 Q1
14 May 22
PBLA
Earnings call transcript
2021 Q4
24 Mar 22
PBLA
Earnings call transcript
2021 Q3
12 Nov 21
Latest ownership filings
SC 13G/A
Lind Global Fund II LP
13 Feb 24
4
Change in insider ownership
13 Nov 23
3
Initial statement of insider ownership
13 Nov 23
4
Jeffrey E. Jacob
14 Sep 23
4
Jennifer K. Simpson
29 Mar 23
4
Susan Horvath
29 Mar 23
4
Michael T. Cullen
29 Mar 23
4
Daniel Donovan
29 Mar 23
4
Arthur Fratamico
29 Mar 23
4
Jeffrey E. Jacob
29 Mar 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 907.00 k | 907.00 k | 907.00 k | 907.00 k | 907.00 k | 907.00 k |
Cash burn (monthly) | 2.10 mm | 2.83 k | 2.62 mm | 2.01 mm | 2.23 mm | 2.26 mm |
Cash used (since last report) | 13.99 mm | 18.89 k | 17.44 mm | 13.40 mm | 14.84 mm | 15.09 mm |
Cash remaining | -13.09 mm | 888.11 k | -16.54 mm | -12.49 mm | -13.93 mm | -14.19 mm |
Runway (months of cash) | -6.2 | 313.5 | -6.3 | -6.2 | -6.3 | -6.3 |
Institutional ownership, Q2 2023
20.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 2 |
Closed positions | 14 |
Increased positions | 0 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 945.12 mm |
Total shares | 1.00 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lind Global Fund II | 590.00 k | $0.00 |
Sabby Management | 235.82 k | $542.38 mm |
Walleye Capital | 94.54 k | $217.43 mm |
Hudson Bay Capital Management | 76.00 k | $174.80 mm |
Tower Research Capital | 3.71 k | $8.54 mm |
UBS UBS Group AG - Registered Shares | 823.00 | $1.89 mm |
MS Morgan Stanley | 26.00 | $60.00 k |
BAC Bank Of America | 2.00 | $5.00 k |
Advisor | 2.00 | $4.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Nov 23 | Goldman Sachs | Common Stock | Sell | Dispose S | Yes | No | 0.71 | 72,874 | 51.74 k | 397,954 |
12 Sep 23 | Jeffrey E. Jacob | Common Stock | Gift | Dispose G | Yes | No | 0 | 275 | 0.00 | 0 |
27 Mar 23 | Schemel Donald Robert | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5 | 8,333 | 4.17 k | 8,333 |
27 Mar 23 | Jeffrey E. Jacob | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5 | 8,333 | 4.17 k | 8,333 |
News
HC Wainwright & Co. Maintains Buy on Panbela Therapeutics, Lowers Price Target to $5
2 Apr 24
Roth MKM Maintains Buy on Panbela Therapeutics, Maintains $25 Price Target
27 Mar 24
Recap: Panbela Therapeutics Q4 Earnings
26 Mar 24
Panbela Therapeutics Q4 2023 GAAP EPS $(65.90) Misses $(24.34) Estimate
26 Mar 24
Earnings Preview: Panbela Therapeutics
25 Mar 24
Press releases
Panbela Announces Transfer to OTCQB Market
16 Apr 24
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
26 Mar 24
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
30 Jan 24
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
29 Jan 24
Thinking about buying stock in Panbela Therapeutics, Netflix, Qualcomm, Cyngn, or Aclarion?
26 Jan 24